5 results on '"Yury S. Polikanov"'
Search Results
2. Structure of Erm-modified 70S ribosome reveals the mechanism of macrolide resistance
- Author
-
Maxim S. Svetlov, Gemma C. Atkinson, Alexander S. Mankin, Elena V. Aleksandrova, Yury S. Polikanov, Egor A Syroegin, and Steven T. Gregory
- Subjects
Methyltransferase ,medicine.drug_class ,nascent peptide exit tunnel ,Methylation ,Ribosome ,Article ,Macrolide Antibiotics ,resistance ,03 medical and health sciences ,chemistry.chemical_compound ,23S ribosomal RNA ,antibiotic ,Drug Resistance, Bacterial ,medicine ,Protein biosynthesis ,Molecular Biology ,030304 developmental biology ,A2058 ,0303 health sciences ,Desosamine ,030302 biochemistry & molecular biology ,RNA ,23S rRNA ,Cell Biology ,inhibition of translation ,Ribosomal RNA ,Anti-Bacterial Agents ,peptidyl transferase center ,RNA, Ribosomal, 23S ,chemistry ,Biochemistry ,RNA, Ribosomal ,Macrolides ,Macrolide ,70S ribosome ,X-ray structure ,Ribosomes - Abstract
Many antibiotics inhibit bacterial growth by binding to the ribosome and interfering with protein biosynthesis. Macrolides represent one of the most successful classes of ribosome-targeting antibiotics. The main clinically relevant mechanism of resistance to macrolides is dimethylation of the 23S rRNA nucleotide A2058, located in the drug-binding site, a reaction catalyzed by Erm-type rRNA methyltransferases. Here, we present the crystal structure of the Erm-dimethylated 70S ribosome at 2.4 A resolution, together with the structures of unmethylated 70S ribosome functional complexes alone or in combination with macrolides. Altogether, our structural data do not support previous models and, instead, suggest a principally new explanation of how A2058 dimethylation confers resistance to macrolides. Moreover, high-resolution structures of two macrolide antibiotics bound to the unmodified ribosome reveal a previously unknown role of the desosamine moiety in drug binding, laying a foundation for the rational knowledge-based design of macrolides that can overcome Erm-mediated resistance. Structural analysis of the A2058-dimethylated and unmethylated 70S ribosome complex alone and in combination with macrolides reveals the role of the desosamine moiety of macrolides in drug binding and resistance.
- Published
- 2021
3. Tetracenomycin X inhibits translation by binding within the ribosomal exit tunnel
- Author
-
Ekaterina S. Komarova, Semen A. Leyn, Yury S. Polikanov, Dmitrii A. Lukianov, Ilya A. Osterman, Dmitrii I. Shiriaev, Sergey E. Dmitriev, Yuliya V. Zakalyukina, Mikhail V. Biryukov, Vadim N. Tashlitsky, Andrei L. Osterman, Robert Buschauer, Daniel N. Wilson, Petr V. Sergiev, Roland Beckmann, Jingdong Cheng, Dmitry A. Skvortsov, Vladimir I. Polshakov, Kseniya A Lashkevich, Jaime E. Zlamal, Tinashe P. Maviza, Olga A. Dontsova, Maximiliane Wieland, and Alexey A. Bogdanov
- Subjects
0303 health sciences ,Chemistry ,Protein subunit ,030302 biochemistry & molecular biology ,Translation (biology) ,Cell Biology ,Plasma protein binding ,Ribosomal RNA ,Cell biology ,03 medical and health sciences ,Protein structure ,23S ribosomal RNA ,Protein biosynthesis ,Binding site ,Molecular Biology ,030304 developmental biology - Abstract
The increase in multi-drug resistant pathogenic bacteria is making our current arsenal of clinically used antibiotics obsolete, highlighting the urgent need for new lead compounds with distinct target binding sites to avoid cross-resistance. Here we report that the aromatic polyketide antibiotic tetracenomycin (TcmX) is a potent inhibitor of protein synthesis, and does not induce DNA damage as previously thought. Despite the structural similarity to the well-known translation inhibitor tetracycline, we show that TcmX does not interact with the small ribosomal subunit, but rather binds to the large subunit, within the polypeptide exit tunnel. This previously unappreciated binding site is located adjacent to the macrolide-binding site, where TcmX stacks on the noncanonical basepair formed by U1782 and U2586 of the 23S ribosomal RNA. Although the binding site is distinct from the macrolide antibiotics, our results indicate that like macrolides, TcmX allows translation of short oligopeptides before further translation is blocked.
- Published
- 2020
4. Tetracenomycin X inhibits translation by binding within the ribosomal exit tunnel
- Author
-
Ilya A, Osterman, Maximiliane, Wieland, Tinashe P, Maviza, Kseniya A, Lashkevich, Dmitrii A, Lukianov, Ekaterina S, Komarova, Yuliya V, Zakalyukina, Robert, Buschauer, Dmitrii I, Shiriaev, Semen A, Leyn, Jaime E, Zlamal, Mikhail V, Biryukov, Dmitry A, Skvortsov, Vadim N, Tashlitsky, Vladimir I, Polshakov, Jingdong, Cheng, Yury S, Polikanov, Alexey A, Bogdanov, Andrei L, Osterman, Sergey E, Dmitriev, Roland, Beckmann, Olga A, Dontsova, Daniel N, Wilson, and Petr V, Sergiev
- Subjects
Models, Molecular ,Binding Sites ,Naphthacenes ,Protein Conformation ,Cryoelectron Microscopy ,Gene Expression Regulation, Bacterial ,Microbial Sensitivity Tests ,HEK293 Cells ,Protein Biosynthesis ,Drug Resistance, Bacterial ,Mutation ,Escherichia coli ,Humans ,Amycolatopsis ,Ribosomes ,Protein Binding - Abstract
The increase in multi-drug resistant pathogenic bacteria is making our current arsenal of clinically used antibiotics obsolete, highlighting the urgent need for new lead compounds with distinct target binding sites to avoid cross-resistance. Here we report that the aromatic polyketide antibiotic tetracenomycin (TcmX) is a potent inhibitor of protein synthesis, and does not induce DNA damage as previously thought. Despite the structural similarity to the well-known translation inhibitor tetracycline, we show that TcmX does not interact with the small ribosomal subunit, but rather binds to the large subunit, within the polypeptide exit tunnel. This previously unappreciated binding site is located adjacent to the macrolide-binding site, where TcmX stacks on the noncanonical basepair formed by U1782 and U2586 of the 23S ribosomal RNA. Although the binding site is distinct from the macrolide antibiotics, our results indicate that like macrolides, TcmX allows translation of short oligopeptides before further translation is blocked.
- Published
- 2020
5. Structural and evolutionary insights into ribosomal RNA methylation
- Author
-
Anastasia A. Chugunova, Petr V. Sergiev, Olga A. Dontsova, Nikolay A. Aleksashin, and Yury S. Polikanov
- Subjects
0301 basic medicine ,Saccharomyces cerevisiae ,RRNA methylation ,Context (language use) ,Methylation ,Ribosome ,03 medical and health sciences ,RNA, Ribosomal, 16S ,Escherichia coli ,Animals ,Humans ,Molecular Biology ,Gene ,Genetics ,Binding Sites ,biology ,Nucleotides ,Ubiquitin ,RNA ,Cell Biology ,Ribosomal RNA ,biology.organism_classification ,RNA, Bacterial ,030104 developmental biology ,RNA, Ribosomal ,Nucleic Acid Conformation ,Ribosomes - Abstract
Methylation of nucleotides in ribosomal RNAs (rRNAs) is a ubiquitous feature that occurs in all living organisms. Identification of all enzymes responsible for rRNA methylation, as well as mapping of all modified rRNA residues, is now complete for a number of model species, such as Escherichia coli and Saccharomyces cerevisiae. Recent high-resolution structures of bacterial ribosomes provided the first direct visualization of methylated nucleotides. The structures of ribosomes from various organisms and organelles have also lately become available, enabling comparative structure-based analysis of rRNA methylation sites in various taxonomic groups. In addition to the conserved core of modified residues in ribosomes from the majority of studied organisms, structural analysis points to the functional roles of some of the rRNA methylations, which are discussed in this Review in an evolutionary context.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.